Quarterly report pursuant to Section 13 or 15(d)

Liquidity

v3.3.0.814
Liquidity
9 Months Ended
Sep. 30, 2015
Accounting Policies [Abstract]  
Liquidity

2.

LIQUIDITY

The Company has incurred recurring losses since inception and as of September 30, 2015, had an accumulated deficit of approximately $10,779,000. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to research funding, development of its product candidates and its preclinical and clinical programs, strategic alliances and the development of its administrative organization. The Company expects the current cash on hand of approximately $13,173,000 to be sufficient to meet its operating and capital requirements into the fourth quarter of 2016. The Company will need to raise significant additional capital to fund the clinical trials for Resunab ™. The Company may seek to sell common or preferred equity or convertible debt securities, enter into a credit facility or another form of third-party funding, or seek other debt financing. The sale of equity and convertible debt securities may result in dilution to the Company’s stockholders and those securities may have rights senior to those of the Company’s common shares. If the Company raises additional funds through the issuance of preferred stock, convertible debt securities or other debt financing, these securities or other debt could contain covenants that would restrict the Company’s operations. Any other third-party funding arrangement could require the Company to relinquish valuable rights.

The source, timing and availability of any future financing will depend principally upon market conditions, and, more specifically, on the progress of the Company’s clinical development programs. Funding may not be available when needed, at all, or on terms acceptable to the Company. Lack of necessary funds may require the Company, among other things, to delay, scale back or eliminate some or all of the Company’s planned clinical trials.